The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Xalkori (crizotinib) for patients between the ages of 1 and 21 years of age with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
The latest development derives largely from results of Study ADVL0912, which showed crizotinib treatment resulted in an objective response rate of 88%, and a complete remission rate of 81%. The safety and efficacy of crizotinib have not been established in older adults with the same condition.
ALCL is a rare type of Non-Hodgkins lymphoma that involves abnormal growth of white blood cells, either T cells or B cells. Anaplastic large cell lymphoma is an aggressive cancer that usually involves the T-cells.
The study included 26 patients with relapsed or refractory, systemic ALK-positive ALCL who had at least one systemic treatment. Patients received crizotinib 280 mg/m2 (20 patients) or 165 mg/m2 (6 patients) orally twice daily until disease progression or unacceptable toxicity. Patients were permitted to discontinue crizotinib to undergo hematopoietic stem cell transplantation. Of the 23 patients who achieved a response, 39% maintained response for at least 6 months, and 22% maintained response for at least 12 months.
The most common adverse reactions (≥35%), excluding laboratory abnormalities, were diarrhea, vomiting, nausea, vision disorder, headache, musculoskeletal pain, stomatitis, fatigue, decreased appetite, pyrexia, abdominal pain, cough, and pruritus. Grade 3-4 laboratory abnormalities (≥15%) were neutropenia, lymphopenia, and thrombocytopenia.
The recommended crizotinib dosage for systemic ALCL is 280 mg/m2 orally twice daily based on body surface area. Complete prescribing information can be found here.
Learn more about rare cancers and the development of new treatments on our exclusive rare cancer page.